– FRANCE, Toulouse / USA, MI – ABIONYX Pharma (EPA: ABNX), today announced that the Board of Directors has taken note of the resignation of its current Chairman, Richard Pasternak, as Director and Chairman of the Board.
The Board elected Emmanuel Huynh as Chairman of the Board and confirmed Cyrille Tupin as Chief Executive Officer. The Board expresses its confidence in its new Chairman and in its CEO and assures them of its full support in their mission.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in immuno-oncology and chemotherapy.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
